- Home
- Z vs NTRA Comparison
Z vs NTRA Comparison
Compare Z & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- Z
- NTRA
- Stock Information
- Founded
- Z 2004
- NTRA 2003
- Country
- Z United States
- NTRA United States
- Employees
- Z N/A
- NTRA N/A
- Industry
- Z Business Services
- NTRA Medical Specialities
- Sector
- Z Consumer Discretionary
- NTRA Health Care
- Exchange
- Z Nasdaq
- NTRA Nasdaq
- Market Cap
- Z 17.0B
- NTRA 18.4B
- IPO Year
- Z 2011
- NTRA 2015
- Fundamental
- Price
- Z $66.46
- NTRA $138.06
- Analyst Decision
- Z Buy
- NTRA Strong Buy
- Analyst Count
- Z 26
- NTRA 17
- Target Price
- Z $81.64
- NTRA $179.00
- AVG Volume (30 Days)
- Z 2.9M
- NTRA 1.9M
- Earning Date
- Z 04-30-2025
- NTRA 05-08-2025
- Dividend Yield
- Z N/A
- NTRA N/A
- EPS Growth
- Z N/A
- NTRA N/A
- EPS
- Z N/A
- NTRA N/A
- Revenue
- Z $2,236,000,000.00
- NTRA $1,696,911,000.00
- Revenue This Year
- Z $16.41
- NTRA $13.56
- Revenue Next Year
- Z $14.79
- NTRA $18.11
- P/E Ratio
- Z N/A
- NTRA N/A
- Revenue Growth
- Z 14.96
- NTRA 56.75
- 52 Week Low
- Z $38.45
- NTRA $83.13
- 52 Week High
- Z $89.39
- NTRA $183.00
- Technical
- Relative Strength Index (RSI)
- Z 38.25
- NTRA 41.35
- Support Level
- Z $69.50
- NTRA $146.35
- Resistance Level
- Z $74.49
- NTRA $155.64
- Average True Range (ATR)
- Z 2.54
- NTRA 6.42
- MACD
- Z 0.11
- NTRA 0.87
- Stochastic Oscillator
- Z 8.00
- NTRA 51.93
About Z Zillow Group Inc. Class C Capital Stock
Zillow Group Inc is an Internet-based real estate company that offers its customers an on-demand experience for selling, buying, renting, or financing with transparency and ease The group works with real estate agents, brokers, builders, property managers, and landlords to pair technology with top-notch service. The group has brands such as Zillow, Trulia, StreetEasy, Hotpads, Zillow Rentals, Zillow Home Loans, ShowingTime, Follow Up Boss, Aryeo and others.
About NTRA Natera Inc.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.